Blog
Monday 19 January 2015
Last week, the Cancer Drugs Fund (CDF) announced the results of its recent review of over 50 cancer drugs, including four ovarian cancer drugs. Our Head of Research, Dr Simon Newman, explains what the decisions mean. Read Annie Mulholland's blog for a patient's perspective Well now the dust has...
Blog
Monday 19 January 2015
Last week, the Cancer Drugs Fund (CDF) announced the results of its recent review of over 50 cancer drugs, including four ovarian cancer drugs. Annie Mulholland has received treatment with Avastin, and tells us about the implications of the review, from her perspective. Read Dr Simon Newman's blog...
News
Thursday 15 January 2015
We're thrilled to announce the launch of our new Clinical Advisory Panel, set up to help us provide better support to you, and anyone concerned about ovarian cancer, through the 'Ask the experts' section of our website. We have assembled a panel of the UK’s leading ovarian cancer experts, including...
News
Tuesday 13 January 2015
The Scottish Medicines Consortium (SMC) has announced the results of its recent review of cancer drugs and was unable to accept bevacizumab (Avastin) for first line treatment of advanced stage ovarian cancer (stage IIIc/IV). Despite patient groups and clinicians highlighting the potential benefits...

Pages